• TRADE NAMES: Acerbon; Alapril; Carace; Coric; Prinil; Prinivil (Merck); Prinzide (Merck); Tensopril; Vivatec; Zestoretic (AstraZeneca); Zestril (AstraZeneca)
  • INDICATIONS: Hypertension; as adjunctive therapy in the management of heart failure; short-term treatment following myocardial infarction in hemodynamically stable patients
  • CLASS: Angiotensin-converting enzyme (ACE) inhibitor
  • HALF-LIFE: 12 hours

Prinzide and Zestoretic are lisinopril and hydrochlorothiazide.

Hydrochlorothiazide is a sulfonamide and can be absorbed systemically. Sulfonamides can produce severe, possibly fatal, reactions such as toxic epidermal necrolysis and Stevens-Johnson syndrome.

Contra-indicated in patients with a history of angioedema related to previous treatment with an ACE inhibitor and in patients with hereditary or idiopathic angioedema.

FETAL TOXICITY

See full prescribing information for complete boxed warning.

Please login to view the rest of this drug profile.

Page last updated 07/31/2023

Symbol key

Incidence

<1% 1‑5% 5‑10% 10‑15% 15‑20% 20‑30% >30%

Seriousness

Hospitalization possible
Life threatening
Fatal

Warnings in other populations

BreastfeedingBreast feeding

GeriatricGeriatric

PediatricPediatric